Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2023 Earnings Conference Call February 5, 2024 5:00 PM ET

Company Participants

Susie Lisa - CFA, Senior Vice President of Investor Relations

Reshma Kewalramani - President & Chief Executive Officer

Stuart Arbuckle - Executive Vice President & Chief Operating Officer

Charlie Wagner - Executive Vice President & Chief Financial Officer

Conference Call Participants

Salveen Richter - Goldman Sachs

Geoff Meacham - Bank of America

Mohit Bansal - Wells Fargo

Phil Nadeau - TD Cowen

Robyn Karnauskas - Truist Securities

Jessica Fye - J.P. Morgan

Evan Seigerman - BMO Capital Markets

Chris Raymond - Piper Sandler

Colin Bristow - UBS

Myles Minter - William Blair

Operator

Good day, and welcome to the Vertex Pharmaceuticals Fourth Quarter 2023 Earnings Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note, this event is being recorded.

I would now like to turn the conference over to Ms. Susie Lisa, please go ahead ma'am.

Susie Lisa

Good evening, everyone. My name is Susie Lisa, and as a Senior Vice President of Investor Relations, it is my pleasure to welcome you to our Fourth Quarter and Full Year 2023 Financial Results Conference Call.

On tonight's call, making prepared remarks, we have Dr. Reshma Kewalramani, Vertex's CEO and President; Stuart Arbuckle, Chief Operating Officer; and Charlie Wagner, Chief Financial Officer. We recommend that you access the webcast slides as you listen to this call. The call is being recorded and a replay will be available on our website.

We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail in today's press release and in our filings with the Securities and Exchange Commission. These statements, including without limitation, those regarding Vertex's marketed medicines for cystic fibrosis, sickle cell disease, and beta thalassemia, our pipeline, and Vertex's future financial performance are based on management's current assumptions. Actual outcomes and events could differ materially.

I would also note that select financial results and guidance that we will review on the call this evening are presented on a non-GAAP basis. In addition, the impact of foreign exchange is presented inclusive of our foreign exchange risk management program.

I will now turn the call over to Reshma.

Reshma Kewalramani

Thanks, Susie. Good evening all, and thank you for joining us on the call today. We've delivered another excellent quarter to finish 2023, established a strong foundation for continued growth, and started off 2024 with tremendous momentum with additional approvals for CASGEVY, positive Phase 3 results for VX-548 in acute pain last week, and positive results for the vanzacaftor triple program in CF, this afternoon.